NEW YORK--(BUSINESS WIRE)--The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired
securities of Aratana Therapeutics, Inc. (NASDAQ: PETX)between
March 16, 2015 and February 3, 2017. You are hereby
notified that Levi & Korsinsky has commenced the class action Dezi
v. Aratana Therapeutics, Inc., et al. (Case No.
1:17-cv-01446) in the USDC for the Southern District of New York. To get
more information go to:

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There
is no cost or obligation to you.

The complaint alleges that throughout the Class Period Defendants made
false and/or misleading statements and/or failed to disclose that: (1)
Aratana did not have manufacturing contracts in place sufficient to
support manufacturing of ENTYCE at a commercial scale; (2) therefore,
ENTYCE was not likely to be commercially available until late 2017; (3)
accordingly, Aratana had misled investors regarding the probable
timeline for a commercial launch of ENTYCE; and (4) consequently,
Aratana’s public statements were materially false and misleading at all
relevant times.

If you suffered a loss in Aratanayou have until April
7, 2017to request that the Court appoint you as lead
plaintiff. Your ability to share in any recovery doesn’t require that
you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York,
California, Connecticut, and Washington D.C. The firm’s attorneys have
extensive expertise and experience representing investors in securities
litigation involving financial fraud, and have recovered hundreds of
millions of dollars for aggrieved shareholders. Attorney advertising.
Prior results do not guarantee similar outcomes.